TY - JOUR TI - Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma AU - Abazis-Stamboulieh, D. AU - Oikonomou, P. AU - Papadoulis, N. AU - Panayiotidis, P. AU - Vrakidou, E. AU - Tsezou, A. JO - Clinical Lymphoma Myeloma and Leukemia PY - 2007 VL - 48 TODO - 11 SP - 2196-2203 PB - SN - null TODO - 10.1080/10428190701615892 TODO - interleukin 1 receptor blocking agent; interleukin 1alpha; interleukin 1beta, adult; aged; article; cancer susceptibility; cell maturation; cell proliferation; controlled study; disease course; DNA polymorphism; female; gene control; genetic predisposition; human; immune system; major clinical study; male; multiple myeloma; priority journal; single nucleotide polymorphism, Adult; Aged; Aged, 80 and over; Case-Control Studies; Female; Gene Frequency; Genotype; Greece; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1alpha; Interleukin-1beta; Linkage (Genetics); Male; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide TODO - Interleukin-1 (IL-1) is a cytokine involved in the maturation and proliferation of B cells and plays a significant role in the development of lytic bone lesions, a major clinical feature of multiple myeloma (MM) patients. Genes that regulate products involved in the immune system are highly polymorphic and contribute to inter-individual differences that can influence the genetic predisposition and progression of particular diseases and cancers. In this study, we investigated the correlation between the single nucleotide polymorphisms IL1A -889, IL1B -511, IL1B +3954, IL1RN Mspa1 +11100 and susceptibility to MM in 74 patients and 160 controls. We found that individuals possessing IL1A -889 CT polymorphism had a higher risk in developing MM. Moreover, genotypes IL1B -511 CC, IL1B +3954 CC, IL-1RN Mspa1 +11100 CC and the combination of IL 1B +3954 CC with IL1B -511 CC or IL-1RN Mspa1 +11100 CC exerted a protective effect in individuals possessing them. ER -